HIGH-RISK NEUROBLASTOMA
Clinical trials for HIGH-RISK NEUROBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK NEUROBLASTOMA trials appear
Sign up with your email to follow new studies for HIGH-RISK NEUROBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising antibody added to standard chemo for tough childhood cancer
Disease control Recruiting nowThis phase II trial is testing whether adding the drug naxitamab (Danyelza) to standard chemotherapy improves outcomes for children newly diagnosed with high-risk neuroblastoma. About 93 participants will receive naxitamab during five cycles of induction chemo. The goal is to see…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE2 • Sponsor: Giselle Sholler • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New drug combo shows promise against childhood cancer
Disease control Recruiting nowThis study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps children with high-risk neuroblastoma, a rare but aggressive childhood cancer. About 144 children and teens aged 18 months to 18 years will receive the combination over up to 12 cy…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE2, PHASE3 • Sponsor: Renaissance Pharma Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New vaccine combo aims to outsmart neuroblastoma relapse
Disease control Recruiting nowThis Phase II trial tests a bivalent vaccine (with an immune booster) plus two different schedules of oral β-glucan in 94 people with high-risk neuroblastoma who are in complete remission. The goal is to see which schedule triggers stronger antibodies against the cancer, potentia…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take aim at childhood cancer
Disease control Recruiting nowThis study tests a new treatment for children and young adults with neuroblastoma that has returned or not responded to standard care. The treatment uses specially engineered immune cells from donated cord blood that are designed to recognize and attack two different markers on t…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could less chemo be enough? new trial aims to treat High-Risk neuroblastoma with reduced therapy
Disease control Recruiting nowThis phase 2 trial is testing whether a reduced chemotherapy regimen called N10 is safe and effective for children with high-risk neuroblastoma. The study will enroll 45 children under 19 years old who have not had more than one prior chemo cycle. The goal is to see if this light…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called GPC2 CAR T cells for children with neuroblastoma or retinoblastoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize a…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on childhood cancer in new trial
Disease control Recruiting nowThis trial tests a new treatment called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, engineering them to recognize and attack cancer…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can financial help ease the burden for families fighting childhood cancer?
Symptom relief Recruiting nowThis study looks at whether adding a special support program (called RISE) to usual care can reduce financial and material hardships for low-income families of children with high-risk neuroblastoma. About 84 children and their parents will take part, with half getting the extra s…
Matched conditions: HIGH-RISK NEUROBLASTOMA
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC